X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
https://www.biopharmadive.com/news/bristol-myers-layoffs-restructuring-cost-savings/714254/
https://www.fiercebiotech.com/biotech/ultimovacs-lays-40-survive-wake-cancer-vaccines-phase-2-fail
https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-liver-cancer-treatment-meets-main-goal-late-stage-study-2024-03-20/
https://www.globenewswire.com//news-release/2024/03/07/2841921/0/en/Ultimovacs-Announces-Topline-Results-from-INITIUM-Study-Evaluating-UV1-Vaccination-Added-to-Ipilimumab-and-Nivolumab-in-Patients-with-Unresectable-or-Metastatic-Malignant-Melanoma.html
https://www.fiercepharma.com/pharma/bristol-myers-unfolds-subcutaneous-opdivo-data-kidney-cancer-i-o-battle-heads-new-front
https://www.globenewswire.com//news-release/2023/12/27/2801365/0/en/SELLAS-Life-Sciences-Reports-Positive-Follow-Up-Immune-Response-and-Survival-Data-in-Completed-Phase-1-Study-of-Galinpepimut-S-Combined-with-Opdivo-in-Advanced-Malignant-Pleural-Me.html
https://www.fiercepharma.com/pharma/bristol-myers-squibbs-opdualag-hits-wall-colorectal-cancer-scrapped-trial
https://www.fiercepharma.com/pharma/seagen-adcetris-and-bristol-opdivo-boost-hopes-another-adc-pd-1-combo
https://www.fiercepharma.com/pharma/bms-shows-success-opdivo-yervoy-combo-first-line-colorectal-cancer
https://www.asiaone.com/business/first-patient-enrolled-phase-iii-clinical-trial-boan-biotechs-nivolumab-injection
https://news.bms.com/news/corporate-financial/2023/European-Medicines-Agency-Validates-Bristol-Myers-Squibbs-Application-for-Opdivo-nivolumab-in-Combination-with-Cisplatin-Based-Chemotherapy-for-the-First-Line-Treatment-of-Adult-Patients-with-Unresectable-or-Metastatic-Urothelial-Carcinoma/default.aspx
https://www.fiercepharma.com/pharma/bristol-myers-opdivo-chalks-bladder-cancer-win-padcev-keytruda-casts-long-shadow
https://news.bms.com/news/corporate-financial/2023/Phase-3-CheckMate--67T-Trial-of-Subcutaneous-Nivolumab-nivolumab-and-hyaluronidase-Meets-Co-Primary-Endpoints-in-Advanced-or-Metastatic-Clear-Cell-Renal-Cell-Carcinoma/default.aspx
https://www.fiercepharma.com/pharma/bristol-myers-squibbs-opdivo-reign-expands-new-earlier-stage-melanoma-nod
https://www.onclive.com/view/fda-approves-adjuvant-nivolumab-for-completely-resected-stage-iib-c-melanoma
https://endpts.com/amgen-readies-phiii-trial-for-first-opdivo-biosimilar-with-launch-unlikely-before-2028/
https://www.onclive.com/view/neoadjuvant-nivolumab-ipilimumab-combo-elicits-responses-safety-in-resectable-hcc
https://www.onclive.com/view/biomarker-analysis-contextualizes-rfs-benefit-with-nivolumab-in-metastatic-melanoma
https://www.fiercepharma.com/pharma/bristol-myers-astrazeneca-settle-pd-1-ctla-4-cancer-immunotherapy-patent-suits-510m
https://www.fiercepharma.com/pharma/bristol-myers-opdivo-makes-comeback-bladder-cancer-teeing-2-merck-showdowns
https://finance.yahoo.com/news/bristol-myers-squibb-receives-european-105900188.html
https://www.onclive.com/view/neoadjuvant-nivolumab-chemo-wins-eu-approval-for-resectable-pd-l1-nsclc
https://www.globenewswire.com/news-release/2023/06/28/2696184/0/en/SELLAS-Life-Sciences-Reports-Positive-Data-in-Completed-Phase-1-Study-of-Galinpepimut-S-Combined-with-Opdivo-in-Advanced-Malignant-Pleural-Mesothelioma.html
https://www.onclive.com/view/galinpepimut-s-plus-nivolumab-provides-survival-benefits-with-acceptable-safety-in-mesothelioma
https://www.prnewswire.com/news-releases/aveo-oncology-announces-completion-of-enrollment-in-pivotal-phase-3-tinivo-2-study-of-fotivda-tivozanib-in-combination-with-opdivo-nivolumab-in-advanced-renal-cell-carcinoma-301864465.html
https://www.fiercepharma.com/pharma/seagens-top-selling-drug-under-threat-bristol-myers-opdivo-beats-adcetris-lymphoma
https://www.fiercebiotech.com/biotech/asco-regeneron-offers-combo-data-hopes-rivaling-bms-opdualag-advanced-melanoma
https://news.bms.com/news/corporate-financial/2023/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-Recommending-Approval-for-Opdivo-nivolumab-with-Chemotherapy-as-Neoadjuvant-Treatment-of-Resectable-Non-Small-Cell-Lung-Cancer-at-High-Risk-of-Recurrence-in-Patients-with-Tumor-Cell-PD-L1-Expre/default.aspx
https://www.prnewswire.com/news-releases/transcenta-to-present-two-clinical-trial-progress-at-asco-2023-301817978.html
Market Place
Share 
